Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302990 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults
A Phase 1 study, sponsored by Medicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT01302990 is a Phase 1 study that has completed, run by Medicago. The registered enrollment target is 100 participants.
The verdict
NCT01302990, a Phase 1 study, has completed, sponsored by Medicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, active- and placebo-controlled, multicenter, dose-ranging study to evaluate the safety, tolerability and Immunogenicity of a single non-adjuvanted dose of the H1 VLP Influenza vaccine in healthy adults 18-49 years of age.
Interventions
- BIOLOGICAL Dose given at Day 0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302990
The ClinicalTrials.gov registry entry for NCT01302990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medicago, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dose given at Day 0 is the first listed.
NCT01302990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302990 about?
NCT01302990 is a clinical study titled "Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults". This is a Phase 1, randomized, double-blind, active- and placebo-controlled, multicenter, dose-ranging study to evaluate the safety, tolerability and Immunogenicity of a single non-adjuvanted dose of the H1 VLP Influenza vaccine in healthy adults 18-49 years of age.
What is the current status of trial NCT01302990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2011-02. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01302990?
The interventions under investigation include: Dose given at Day 0 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01302990?
This trial is sponsored by Medicago, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.